GlassScriptPhysician profile
Robert K Talton
NPI 1356318828
$6,250.90
in general payments reported to CMS, 2019-2025
49 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $871 · 2021: $1,490 · 2022: $1,150 · 2023: $627 · 2024: $422 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $878.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $658.20 | 2019-2025 | Wegovy |
| Abbvie INC. | $429.04 | 2019-2022 | |
| Amgen INC. | $350.15 | 2019-2022 | |
| Astellas Pharma US INC | $240.53 | 2019-2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $239.52 | 2019-2022 | |
| Corcept Therapeutics | $234.39 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $218.05 | 2020-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $211.52 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $196.93 | 2019-2025 | Zepbound, Mounjaro, Amyvid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.23 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $155.90 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $144.98 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $136.65 | 2020-2022 | |
| Corium, LLC | $121.84 | 2023 | Adlarity |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Talton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.